ÂÜÀòÂÒÂ×

Peter has vast experience in the development cancer treatments, including DDR programmes, and particularly their translation to the clinic. Prior to joining Artios, Peter served as Vice President Oncology and Renal Medicine and Site Head for Genzyme Europe Research, with global responsibility for oncology translational research.

He previously served as Chief Medical Officer at Algeta (acquired by Bayer AG in 2013) where he initiated the successful global registration study of Xofigo, formerly alpharadin, the first alpha-emitter approved to market.

Peter was previously Development Director at KuDOS Pharmaceuticals in Cambridge, UK where he was responsible for the preclinical and clinical development of DDR modifiers including Lynparza â„¢ (olaparib).

He also served as Head of Medical Affairs and chair of the global clinical operations group at ICI Pharmaceuticals (now AstraZeneca).

After his BSc (Hons) at UCL, Peter gained his medical qualifications at the University of London.